What Makes Semaglutide Different Uses a single hormone pathway (GLP-1) to support appetite control Often a great option for patients who prefer a more gradual approach Well-studied with a long track record in metabolic care What Makes Tirzepatide Different Activates two hormone pathways (GLP-1 and GIP) for broader metabolic support May provide stronger appetite suppression for some patients Often considered for patients who need additional metabolic support or have experienced plateaus What Clinical Trials Show GLP-1s Can Do The Proof in the Data Semaglutide By week 68, 86.4% lost at least 5%, 69.1% lost at least 10%, and 50.5% lost at least 15%
This hormones ability to impact both physical and mental well-being makes it a powerful target for enhancing whole-body health
The results were striking: Genes upregulated by GHK-Cu include: Collagen I, III, and VII synthesis genes (structural repair) Decorin and proteoglycan genes (extracellular matrix integrity) Antioxidant defense genes (SOD2, catalase, glutathione peroxidase) BDNF and nerve growth factor genes (neural repair and neuroprotection) Anti-inflammatory cytokine genes (IL-10, TGF-1) Angiogenesis genes (VEGF, angiopoietin new blood vessel formation) Stem cell self-renewal pathways Genes downregulated by GHK-Cu include: Pro-inflammatory cytokines (TNF-, IL-6, IL-1) Matrix metalloproteinases MMP-1, MMP-3 (enzymes that degrade collagen and connective tissue) Oxidative stress genes Pathways associated with cancer progression and metastasis The pro-inflammatory gene suppression is particularly notable
GLP-1 medications reduce hepatic glucose production and improve insulin sensitivity, making them especially effective for metabolically compromised individuals
CO = crossover
